Literature DB >> 23000648

Peri-engraftment syndrome in allogeneic hematopoietic SCT.

K T Hong1, H J Kang, N H Kim, M S Kim, J W Lee, H Kim, K D Park, H Y Shin, H S Ahn.   

Abstract

Engraftment syndrome (ES) and pre-engraftment syndrome (pre-ES) are both inflammatory conditions that occur after hematopoietic SCT (HSCT) and are characterized by non-infectious fever and skin rash. Although the pathogenesis is not fully understood, both syndromes are similar, and could be defined as a new clinical syndrome, named as peri-engraftment syndrome (peri-ES). We retrospectively analyzed the clinical records in 176 pediatric patients, following allogeneic HSCT. We utilized the definition of ES by Spitzer as the diagnostic criteria, excluding 'within 96 h of engraftment' criteria. Thirty cases developed peri-ES with a cumulative incidence of 17.0%. High cumulative incidence (50%) was seen in patients who underwent a double-unit cord blood transplantation (DUCBT; P<0.01). Clinical findings of peri-ES are similar, regardless of the onset day, and encephalopathy was the most severe complication. In the DUCBT cohort, the use of TBI and early complete chimerism (≤ day 21) were identified as risk factors that predispose the development of peri-ES. We determined that both, ES and pre-ES, might have similar causes, which could be included in peri-ES. Particularly, it occurred more in DUCBT patients, which means that not only neutrophil engraftment but also immune reactions within the two units might contribute to peri-ES.

Entities:  

Mesh:

Year:  2012        PMID: 23000648     DOI: 10.1038/bmt.2012.171

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

Review 1.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

2.  Bloodstream Infections and Delayed Antibiotic Coverage Are Associated With Negative Hospital Outcomes in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Joyce Ji; Jeff Klaus; Jason P Burnham; Andrew Michelson; Colleen A McEvoy; Marin H Kollef; Patrick G Lyons
Journal:  Chest       Date:  2020-06-17       Impact factor: 9.410

3.  Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.

Authors:  M A Diaz; A Pérez-Martínez; B Herrero; N Deltoro; I Martinez; M Ramirez; L Abad; J Sevilla; E Merino; J Ruiz; J L Vicario; M Gonzalez-Vicent
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

4.  Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Authors:  Lawrence Chang; David Frame; Thomas Braun; Erin Gatza; David A Hanauer; Shuang Zhao; John M Magenau; Kathryn Schultz; Hemasri Tokala; James L M Ferrara; John E Levine; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

5.  Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation.

Authors:  Kyle R Brownback; Steven Q Simpson; Joseph P McGuirk; Tara L Lin; Sunil Abhyankar; Siddhartha Ganguly; Omar S Aljitawi
Journal:  Ann Hematol       Date:  2013-12-18       Impact factor: 3.673

6.  Dexamethasone palmitate for patients with engraftment syndrome is associated with favorable outcome for children with hematological malignancy.

Authors:  H Sakaguchi; K Matsumoto; N Yoshida; K Narita; M Hamada; S Kataoka; N Miyagawa; T Yoshikawa; M Ito; K Kato
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

Review 7.  Pre-engraftment syndrome: clinical significance and pathophysiology.

Authors:  Young-Ho Lee; Wee-Jin Rah
Journal:  Blood Res       Date:  2016-09-23

Review 8.  Umbilical cord blood transplantation: Still growing and improving.

Authors:  Xiaoyu Zhu; Baolin Tang; Zimin Sun
Journal:  Stem Cells Transl Med       Date:  2021-11       Impact factor: 6.940

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.